logo
Is vitamin D deficiency linked to cancer? Here's what an oncologist wants you to know

Is vitamin D deficiency linked to cancer? Here's what an oncologist wants you to know

Sinar Daily21-06-2025
VITAMIN D is commonly known for its role in maintaining healthy bones, but questions have arisen about whether a deficiency in this essential nutrient could also increase the risk of developing serious diseases like cancer.
Health professionals and researchers have long explored the broader impact of vitamin D on the body, with some attention now turning towards its potential link to cancer risk. Although online discussions on the topic are growing, the scientific community remains cautious in interpreting the data.
So, what does the current research actually say?
According to a health portal referencing the National Cancer Institute, possible links between vitamin D levels and cancer mortality have generally been studied across all types of cancer combined. Most meta-analyses of observational studies found that lower serum vitamin D levels were associated with higher overall cancer mortality.
One such analysis of 12 cohort studies reported a 14 per cent increase in cancer-related deaths among individuals with the lowest levels of 25-hydroxyvitamin D, compared to those with the highest levels. Similarly, another study involving around 4,000 cancer cases from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial revealed a 17 per cent reduction in cancer mortality among participants with the highest vitamin D levels.
Various studies also indicated an inverse relationship between vitamin D levels and several types of cancer, including prostate, multiple myeloma, colorectal, and breast cancer. However, expert warned that these findings did not amount to definitive proof, as the studies were largely observational and could not establish a direct cause-and-effect relationship.
As such, many concluded that more high-quality, long-term research was necessary to fully understand the complex role vitamin D might play in cancer development.
The more pressing question, however, is whether vitamin D is essential to the body in the first place.
The Mayo Clinic stated that vitamin D is indeed a vital nutrient required for calcium absorption and bone health. It noted that calcium, a major component of bones, cannot be effectively absorbed without adequate vitamin D levels.
In addition to its bone-related functions, vitamin D also supported immune health and played a role in muscle and brain cell function. But was it a miracle solution against cancer? Expert said no at least not yet, and cautioned against drawing premature conclusions without stronger scientific evidence. Hospital Picaso, Consultant Clinical Oncologist, Dr Mastura Md Yusof
Hospital Picaso, Consultant Clinical Oncologist, Dr Mastura Md Yusof stressed that there was currently no solid evidence to confirm a clear link between low vitamin D levels and an increased risk of cancer.
"The current understanding is that there is still insufficient evidence to show a clear correlation between vitamin D levels and certain cancers.
'Researchers say further studies are needed, that's usually the conclusion when you read about it, because the evidence remains inconclusive,' she said when met here at Hospital Picaso at Petaling Jaya.
Dr Mastura stated that much of the existing research remained small-scale and retrospective, and despite its popularity online, the topic lacked definitive scientific backing.
She emphasised that most studies ended with the conclusion that further research was needed, a clear sign that the evidence was not yet strong enough to confirm a direct connection.
She pointed out that no large, well-designed prospective studies had been conducted to follow individuals over time to assess whether their vitamin D intake or blood levels influenced their likelihood of developing cancer.
She said that such studies involving thousands of participants and rigorous monitoring were necessary to produce what the medical community referred to as 'Level One' evidence. Without this level of proof, no major global health authorities such as the FDA, EMA, or WHO had made formal recommendations regarding vitamin D and cancer prevention. Vitamin D is indeed a vital nutrient required for calcium absorption and bone health. - CANVA
Dr Mastura stressed that most studies currently available online were either retrospective or based on smaller sample sizes, and did not meet the criteria for high-impact, peer-reviewed clinical guidance.
"So whatever is available out there, especially on the internet, isn't really this type of study, most of them are either mouse studies or retrospective studies," she added.
However, Dr Mastura highlighted promising results for a specific group, in which breast cancer survivors.
She referred to a study presented in December at the San Antonio Breast Cancer Symposium, which found that women who had completed treatment for stage one to stage three breast cancer and were taking calcium with vitamin D during their follow-up showed improved outcomes and reduced risk of cancer recurrence.
She clarified that the study applied only to breast cancer survivors who were no longer in advanced stages of the disease. In these cases, oncologists could consider recommending calcium and vitamin D supplementation based on the available data.
However, she said she would not advise the same approach for patients with colorectal or other types of cancer, as the findings did not extend to those groups.
While vitamin D plays a crucial role in overall health, current evidence does not support a direct link between its deficiency and cancer development.
Observational studies have shown some associations, but no conclusive proof. For now, experts urge caution and call for further research before making definitive recommendations.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New medical innovations to address rising cancer burden in Malaysia
New medical innovations to address rising cancer burden in Malaysia

The Star

time4 days ago

  • The Star

New medical innovations to address rising cancer burden in Malaysia

The Hospital Picaso medical team is showcasing a cutting-edge, minimally invasive therapy for patients with prostate cancer. Prostate, pancreatic and liver cancers remain among the most pressing health challenges in Malaysia, with late-stage diagnoses continuing to impact patient outcomes. Prostate cancer is one of the most common cancers affecting Malaysian men, with many cases detected only at advanced stages. Liver cancer is also one of the most common cancers among Malaysians, while pancreatic cancer remains one of the deadliest due to late detection and limited treatment options. In Petaling Jaya, Hospital Picaso – a dedicated centre of excellence for advanced surgery and integrated oncology – is responding to these challenges with next-generation treatment options. It is the leading hospital in Malaysia to offer Irreversible Electroporation (IRE), a non-thermal ablation technique that targets cancer cells while sparing healthy tissue. This innovation represents a significant advancement in prostate cancer care, giving patients more precise options with fewer long-term complications. 'This technique gives us a targeted way to treat prostate cancer, while reducing damage to surrounding structures,' said Hospital Picaso consultant urologist Datuk Dr Loh Chit Sin. 'This treatment can help patients to retain urinary continence and preserve erectile dysfunction. 'These outcomes address two of the biggest concerns men face – maintaining quality of life while seeking effective care.' Known as Irreversible Electro­poration (IRE), this technique utilises high-voltage electrical pul­ses to destroy cancer cells without the use of heat. This method allows treatment near delicate structures, such as nerves, ducts and blood vessels, making it suitable for tumours in the prostate as well as liver, pancreas and kidneys. It reflects a more personalised approach to cancer care that supports both survival and post-­treatment well-being. Building on this advancement, Hospital Picaso is also introducing the Electrochemotherapy (ECT), further expanding its interventional oncology capabilities. ECT combines short electrical pulses with localised chemotherapy to enhance drug absorption directly into tumour cells. It is particularly effective for difficult-to-access or previously unresponsive tumours in the liver and pancreas. By concentrating treatment where it's needed most, while limiting systemic side effects, ECT offers new hope to patients with limited options. New technologies are expanding what's possible but early detection is still key to better outcomes. 'When we detect prostate, pancreatic or liver cancer early, we're able to offer options that are less invasive and more targeted,' said Dr Loh. 'With techniques like Irreversible Electroporation and Electrochemotherapy, we're not just treating the disease – we're giving patients more control over their treatment journey.' At Hospital Picaso, these innovations represent more than medical advancement. They mark a shift in how cancer care is delivered – giving patients better options, making treatments more precise and helping people live more fully during and after recovery. KKLIU: 2321/EXP 31.12.2027

One scan to identify nine types of dementia
One scan to identify nine types of dementia

The Star

time14-07-2025

  • The Star

One scan to identify nine types of dementia

Imagine being able to scan the brain and identify nine types of dementia, including Alzheimer's disease. This AI tool could be tremendously helpful, especially in hospitals that lack neurologists. — TNS A new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, using a single, widely-available scan, has been developed by researchers in the United States. The tool, StateViewer, helped identify the dementia type in 88% of cases, according to a study published online on June 27 (2025) in Neurology , the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. The researchers from Mayo Clinic trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease – the most common form – is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. 'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' says Mayo Clinic Neurology Artificial Intelligence Program director and neurologist Dr David Jones, who directed the development of the tool. 'That complexity drew me to neurology and continues to drive my commitment to clearer answers. 'StateViewer reflects that commitment – a step toward earlier understanding, more precise treatment, and one day, changing the course of these diseases.' To bring that vision to life, he worked alongside data scientist Dr Leland Barnard, who leads the AI engineering behind StateViewer. 'As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,' Dr Barnard says. 'Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.' The tool analyses a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. ALSO READ: Using radiotracers and PET scans to diagnose dementia It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behaviour. ALSO READ: What is frontotemporal dementia? Bruce Willis' condition explained The AI tool displays these patterns through colour-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. The researchers plan to expand the tool's use and will continue evaluating its perfor­mance in a variety of clinical settings. – Mayo Clinic News Network/Tribune News Service

Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management

Malay Mail

time12-07-2025

  • Malay Mail

Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity. The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing. References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.​ World Obesity. Retrieved from World Obesity. Retrieved from Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy(semaglutide 2.4mg) in (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake. This mechanism supports weight loss when combined with sustainable lifestyle availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity, a condition associated with more than 200 health complications. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, "Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity"Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight Vincent Siow, General Manager, Novo Nordisk Singapore, said "With treatments like Wegovy(semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes."Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store